Please ensure Javascript is enabled for purposes of website accessibility

Will Mix-and-Match COVID Boosters Be Allowed?

By Keith Speights and Brian Orelli, PhD – Aug 28, 2021 at 7:01AM

Key Points

  • Americans will soon begin receiving third doses of messenger RNA vaccines.
  • The Food and Drug Administration and Centers for Disease Control and Prevention aren't recommending a booster dose of a vaccine that's different than an individual received previously at this point.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Federal healthcare agencies aren't recommending them at this point.

Mix-and-match COVID-19 vaccines? The idea is that a person who received a previous dose of one vaccine might receive another dose from a different vaccine.

Now that the U.S. government has announced that third booster doses are on the way for Americans who have been fully vaccinated with messenger RNA vaccines, the mix-and-match possibility will likely receive more attention.

In this Motley Fool Live video recorded on Aug. 18, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not mix-and-match will be an option with mRNA booster doses.

10 stocks we like better than Pfizer
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of August 9, 2021

 

Keith Speights: I know we're out of time, but Marita asks a question, "Can a person who has had both Pfizer (PFE 0.74%) vaccines get a Moderna (MRNA -0.23%) booster and vice versa? Also, if a person who had J&J (JNJ 0.13%) vaccine prefers the mRNA type vaccine, what are the options?"

As far as I know, Brian, it's not looking like the FDA is going to come out and say, "Mix and match." At least that's not what I've seen thus far.

Brian Orelli: Yeah. We'll have to see what the FDA ends up doing. But there's some data that suggest that Johnson & Johnson vaccine followed by a Moderna vaccine is actually better than, or just an mRNA vaccine in general is better than actually two mRNA vaccines. We'll have to wait and see exactly what data the FDA believes and then figure out the recommendations from there.

I think at some point, mixing and matching is probably almost certainly going to happen. If we're getting into a fourth booster dose, at that point, I think you're just going to go into the pharmacy or wherever you're getting your doctor's office, and you're just going to get whatever vaccine they have right now.

You don't want to ask what kind of flu vaccine you got last year and then get the same flu vaccine this year. I think that will be at that point, at some point, but I don't know if we're there yet. I don't know if the FDA is comfortable with that idea quite yet.

Speights: The long-term could be different than the near term.

Keith Speights owns shares of Pfizer. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.24 (0.13%) $0.23
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.